|
CN101687786A
|
|
Hydroxylamine compounds and methods of their use
|
|
CA2678363A1
|
|
Drug resistance reversal in neoplastic disease
|
|
CN101389336A
|
|
Hydroxylamines and derivatives for the inhibition of complement activation
|
|
AU2007221271A1
|
|
Hydroxylamines and derivatives for the inhibition of complement activation
|
|
AU2007212116A1
|
|
Hydroxylamines and derivatives as anti-angiogenic agents
|
|
US2006292190A1
|
|
Amelioration of vitrectomy-induced cataracts
|
|
EP1689354A2
|
|
Amelioration of cataracts, macular degeneration and other ophthalmic diseases
|
|
US7825134B2
|
|
Amelioration of cataracts, macular degeneration and other ophthalmic diseases
|
|
AU2004293105A1
|
|
Amelioration of macular degeneration and other ophthalmic diseases
|
|
CN1653125A
|
|
Amelioration of the development of cataracts and other ophthalmic diseases
|
